Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

18-year-old dies after having AstraZeneca vaccine

18-year-old dies after having AstraZeneca vaccine

Case has raised concerns about using the jab on young people

ROME, 11 June 2021, 10:34

Redazione ANSA

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

An 18-year-old woman died at Genoa's San Martino hospital on Thursday after suffering a blood clot following vaccination with the AstraZeneca jab on May 25.
    A causal link between the death of Camilla Canepa and the vaccination has not been established, however.
    Canepa, who was from the town of Sestri Levante in Liguria, was given the jab during a vaccination 'open day' for over 18s.
    The case has raised concerns about the use of the AstraZeneca vaccine on young people.
    The AstraZeneca jab has been approved for all over-18s, but in Italy it is only recommended for over-60s due to links to rare cases of blood clots in younger people.
    This, however, is not an outright ban and the AstraZeneca jab is widely being used in Italy for under-60s, especially since the government made it possible for all adult age groups to book vaccinations, not just the oldest and people considered vulnerable.
    The question has come to the fore with many young people keen to get vaccinated on a voluntary basis to obtain the Green Pass enabling them to travel and attend certain events.
    Liguria Governor Giovanni Toti said Friday that Canepa's case should not be used for point scoring, stressing that that "the option of using AstraZeneca for everyone on a voluntary basis was not invented by the regional governments or by a Dr Strangelove, it was suggested by the top technical-scientific bodies in order to increase vaccinations and, therefore, prevent deaths".
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.